Inicio
Detalle del título uniforme
Clinical Infectious Diseases
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (5)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaReply to Karakonstantis, et al; Zervou and Zacharioudakis; and Rasmussen, et al / Juan Sebastián Peinado Acevedo
Título : Reply to Karakonstantis, et al; Zervou and Zacharioudakis; and Rasmussen, et al Tipo de documento : documento electrónico Autores : Juan Sebastián Peinado Acevedo, Fecha de publicación : 2022 Títulos uniformes : Clinical Infectious Diseases Idioma : Inglés (eng) Mención de responsabilidad : Juan Sebastián Peinado-Acevedo, Juan José Hurtado-Guerra, Carolina Hincapié-Osorno, Juanita Mesa-Abad, José Roberto Uribe-Delgado, Santiago Giraldo-Ramírez, Paula A Lengerke-Diaz, Fabián Jaimes Referencia : Clin Infect Dis. 2022 Jan 7;74(1):167-168. DOI (Digital Object Identifier) : 10.1093/cid/ciab423 PMID : 33972986 En línea : https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab423/6273389 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5793 Reply to Karakonstantis, et al; Zervou and Zacharioudakis; and Rasmussen, et al [documento electrónico] / Juan Sebastián Peinado Acevedo, . - 2022.
Obra : Clinical Infectious Diseases
Idioma : Inglés (eng)
Mención de responsabilidad : Juan Sebastián Peinado-Acevedo, Juan José Hurtado-Guerra, Carolina Hincapié-Osorno, Juanita Mesa-Abad, José Roberto Uribe-Delgado, Santiago Giraldo-Ramírez, Paula A Lengerke-Diaz, Fabián Jaimes Referencia : Clin Infect Dis. 2022 Jan 7;74(1):167-168. DOI (Digital Object Identifier) : 10.1093/cid/ciab423 PMID : 33972986 En línea : https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab423/6273389 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5793 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001724 AC-2021-043 Archivo digital Producción Científica Artículos científicos Disponible
Accompagne Reply to Karakonstantis, et al; Zervou and Zacharioudakis; and Rasmussen, et al / Juan Sebastián Peinado Acevedo
Título : Validation of VIRSTA and Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) Scores to Determine the Priority of Echocardiography in Patients With Staphylococcus aureus Bacteremia Tipo de documento : documento electrónico Autores : Juan Sebastián Peinado Acevedo, Fecha de publicación : 2021 Títulos uniformes : Clinical Infectious Diseases Idioma : Inglés (eng) Palabras clave : Bacteremia Echocardiography Endocarditis Staphylococcal Infections Staphylococcus aureus Resumen : Introduction: Infective endocarditis (IE) secondary to Staphylococcus aureus bacteremia (SAB) has high morbidity and mortality. The systematic use of echocardiography in SAB is controversial. We aimed to validate VIRSTA and PREDICT scores for predicting the risk of IE in Colombian patients with SAB and, consequently, to determine the need for echocardiography. Methodology: Cohort of patients hospitalized with SAB in two high complexity institutions in Medellin, Colombia, between 2012-2018. The diagnosis of IE was established based on the modified Duke criteria. The VIRSTA and PREDICT scores were calculated from the clinical records, and their operational performance was calculated. Results: The final analysis included 922 patients, 62 (6.7%) of whom were diagnosed with IE. The frequency of IE in patients with a negative VIRSTA scale was 0.44% (2/454). The frequency of IE in patients with a negative PREDICT scale on day 5 was 4.8% (30/622). The sensitivity and negative predictive value (NPV) of the VIRSTA scale was 96.7% and 99.5%, respectively. For the PREDICT scale on day 5, the sensitivity and NPV were 51.6% and 95.1%, respectively. The discrimination, given by the area under the ROC curve (AUC), was 0.86 for VIRSTA and 0.64 for PREDICT. Conclusions: In patients with negative VIRSTA, screening echocardiography may be unnecessary due to the low frequency of IE. In PREDICT-negative patients, despite the low frequency of IE, it is not safe to omit echocardiography. Mención de responsabilidad : Juan Sebastián Peinado-Acevedo, Juan José Hurtado-Guerra, Carolina Hincapié, Juanita Mesa-Abad, José Roberto Uribe-Delgado, Santiago Giraldo-Ramírez, Paula A Lengerke-Diaz, Fabián Jaimes Referencia : Clin Infect Dis. 2021 Sep 7;73(5):e1151-e1157. DOI (Digital Object Identifier) : 10.1093/cid/ciaa1844 PMID : 33537758 En línea : https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1844/6127448 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5774 Validation of VIRSTA and Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) Scores to Determine the Priority of Echocardiography in Patients With Staphylococcus aureus Bacteremia [documento electrónico] / Juan Sebastián Peinado Acevedo, . - 2021.
Accompagne Reply to Karakonstantis, et al; Zervou and Zacharioudakis; and Rasmussen, et al / Juan Sebastián Peinado Acevedo
Obra : Clinical Infectious Diseases
Idioma : Inglés (eng)
Palabras clave : Bacteremia Echocardiography Endocarditis Staphylococcal Infections Staphylococcus aureus Resumen : Introduction: Infective endocarditis (IE) secondary to Staphylococcus aureus bacteremia (SAB) has high morbidity and mortality. The systematic use of echocardiography in SAB is controversial. We aimed to validate VIRSTA and PREDICT scores for predicting the risk of IE in Colombian patients with SAB and, consequently, to determine the need for echocardiography. Methodology: Cohort of patients hospitalized with SAB in two high complexity institutions in Medellin, Colombia, between 2012-2018. The diagnosis of IE was established based on the modified Duke criteria. The VIRSTA and PREDICT scores were calculated from the clinical records, and their operational performance was calculated. Results: The final analysis included 922 patients, 62 (6.7%) of whom were diagnosed with IE. The frequency of IE in patients with a negative VIRSTA scale was 0.44% (2/454). The frequency of IE in patients with a negative PREDICT scale on day 5 was 4.8% (30/622). The sensitivity and negative predictive value (NPV) of the VIRSTA scale was 96.7% and 99.5%, respectively. For the PREDICT scale on day 5, the sensitivity and NPV were 51.6% and 95.1%, respectively. The discrimination, given by the area under the ROC curve (AUC), was 0.86 for VIRSTA and 0.64 for PREDICT. Conclusions: In patients with negative VIRSTA, screening echocardiography may be unnecessary due to the low frequency of IE. In PREDICT-negative patients, despite the low frequency of IE, it is not safe to omit echocardiography. Mención de responsabilidad : Juan Sebastián Peinado-Acevedo, Juan José Hurtado-Guerra, Carolina Hincapié, Juanita Mesa-Abad, José Roberto Uribe-Delgado, Santiago Giraldo-Ramírez, Paula A Lengerke-Diaz, Fabián Jaimes Referencia : Clin Infect Dis. 2021 Sep 7;73(5):e1151-e1157. DOI (Digital Object Identifier) : 10.1093/cid/ciaa1844 PMID : 33537758 En línea : https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1844/6127448 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5774 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001699 AC-2021-024 Archivo digital Producción Científica Artículos científicos Disponible
Título : A 40 year old woman from a native indian community with non hodgkin lymphoma and hemoptysis Tipo de documento : documento electrónico Autores : Viviana Patricia Olaya Colorado, Fecha de publicación : 2013 Títulos uniformes : Clinical Infectious Diseases Idioma : Inglés (eng) Mención de responsabilidad : Isabel C. Ramírez, Juan F. Combariza, Viviana Olaya, Pablo Villa Referencia : Clin Infect Dis. 2013 Sep;57(5):765-6. DOI (Digital Object Identifier) : 10.1093/cid/cit409 En línea : https://academic.oup.com/cid/article/57/5/765/313157 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3722 A 40 year old woman from a native indian community with non hodgkin lymphoma and hemoptysis [documento electrónico] / Viviana Patricia Olaya Colorado, . - 2013.
Obra : Clinical Infectious Diseases
Idioma : Inglés (eng)
Mención de responsabilidad : Isabel C. Ramírez, Juan F. Combariza, Viviana Olaya, Pablo Villa Referencia : Clin Infect Dis. 2013 Sep;57(5):765-6. DOI (Digital Object Identifier) : 10.1093/cid/cit409 En línea : https://academic.oup.com/cid/article/57/5/765/313157 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3722 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000295 AC-2013-063 Archivo digital Producción Científica Artículos científicos Disponible
Título : An Incidental Finding From a Blood Smear Tipo de documento : documento electrónico Autores : Alicia Inés Hidrón Botero, ; Kenny Mauricio Gálvez Cárdenas, ; Lina Marcela Arcila Duque, ; Juan Camilo Pérez Cadavid, ; Alejandro Vélez Hoyos, Fecha de publicación : 2012 Títulos uniformes : Clinical Infectious Diseases Idioma : Inglés (eng) Mención de responsabilidad : Alicia Hidron, Kenny Gálvez, Camilo Madrid, Adolfo Vélez, Lina M. Arcila, Juan Camilo Perez, Alejandro Vélez Referencia : Clin Infect Dis. 2012;55(1):155-6. DOI (Digital Object Identifier) : 10.1093/cid/cis125 En línea : https://academic.oup.com/cid/article/55/1/155/317202 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3597 An Incidental Finding From a Blood Smear [documento electrónico] / Alicia Inés Hidrón Botero, ; Kenny Mauricio Gálvez Cárdenas, ; Lina Marcela Arcila Duque, ; Juan Camilo Pérez Cadavid, ; Alejandro Vélez Hoyos, . - 2012.
Obra : Clinical Infectious Diseases
Idioma : Inglés (eng)
Mención de responsabilidad : Alicia Hidron, Kenny Gálvez, Camilo Madrid, Adolfo Vélez, Lina M. Arcila, Juan Camilo Perez, Alejandro Vélez Referencia : Clin Infect Dis. 2012;55(1):155-6. DOI (Digital Object Identifier) : 10.1093/cid/cis125 En línea : https://academic.oup.com/cid/article/55/1/155/317202 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3597 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000167 AC-2012-007 Archivo digital Producción Científica Artículos científicos Disponible
Título : A pan-american 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host Tipo de documento : documento electrónico Autores : Ángela Restrepo Moreno, Fecha de publicación : 1992 Títulos uniformes : Clinical Infectious Diseases Idioma : Inglés (eng) Resumen : Eighty-eight immunocompetent patients with deep mycoses from eight countries were evaluated with the same protocol for efficacy of fluconazole monotherapy. Entry doses were raised from 100 to 400 mg as safety was shown in initial cohorts, and dosages up to 2,400 mg daily and durations up to 44 months were studied. Results were very similar in different countries. Twenty-seven of 28 evaluable patients with paracoccidioidomycosis, 13 of 19 with sporotrichosis, 14 of 16 with coccidioidomycosis, and eight of eight with histoplasmosis demonstrated objective responses to therapy, as did one patient each with zygomycosis and alternariosis. For these patients, relapses have been unusual thus far. In contrast, one patient with chromoblastomycosis responded but relapsed, and six did not respond; one patient with mycetoma responded but relapsed, and two did not respond. The drug was well tolerated by patients, including six who received intravenous therapy. In vitro susceptibility tests suggested that clinical response was correlated with susceptibility but that resistance did not preclude clinical response. Fluconazole therapy appears efficacious for several deep mycoses; dosages of >200 mg daily may be needed for some diseases. The further evaluation of fluconazole for these entities is warranted. Mención de responsabilidad : Manuel Diaz, Ricardo Negroni, Fernando Montero-Gei, Luiz G. M. Castro, Sebastiao A. P. Sampaio, Dante Borelli, Angela Restrepo, Liliana Franco, Jose L. Bran, Eduardo G. Arathoon, David A. Stevens other investigators of the Fluconazole Pan-American Study Group Referencia : Clin Infect Dis. 1992 Mar;14 Suppl 1:S68-76. DOI (Digital Object Identifier) : 10.1093/clinids/14.Supplement_1.S68 PMID : 1562698 En línea : https://academic.oup.com/cid/article-abstract/14/Supplement_1/S68/366004 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4367 A pan-american 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host [documento electrónico] / Ángela Restrepo Moreno, . - 1992.
Obra : Clinical Infectious Diseases
Idioma : Inglés (eng)
Resumen : Eighty-eight immunocompetent patients with deep mycoses from eight countries were evaluated with the same protocol for efficacy of fluconazole monotherapy. Entry doses were raised from 100 to 400 mg as safety was shown in initial cohorts, and dosages up to 2,400 mg daily and durations up to 44 months were studied. Results were very similar in different countries. Twenty-seven of 28 evaluable patients with paracoccidioidomycosis, 13 of 19 with sporotrichosis, 14 of 16 with coccidioidomycosis, and eight of eight with histoplasmosis demonstrated objective responses to therapy, as did one patient each with zygomycosis and alternariosis. For these patients, relapses have been unusual thus far. In contrast, one patient with chromoblastomycosis responded but relapsed, and six did not respond; one patient with mycetoma responded but relapsed, and two did not respond. The drug was well tolerated by patients, including six who received intravenous therapy. In vitro susceptibility tests suggested that clinical response was correlated with susceptibility but that resistance did not preclude clinical response. Fluconazole therapy appears efficacious for several deep mycoses; dosages of >200 mg daily may be needed for some diseases. The further evaluation of fluconazole for these entities is warranted. Mención de responsabilidad : Manuel Diaz, Ricardo Negroni, Fernando Montero-Gei, Luiz G. M. Castro, Sebastiao A. P. Sampaio, Dante Borelli, Angela Restrepo, Liliana Franco, Jose L. Bran, Eduardo G. Arathoon, David A. Stevens other investigators of the Fluconazole Pan-American Study Group Referencia : Clin Infect Dis. 1992 Mar;14 Suppl 1:S68-76. DOI (Digital Object Identifier) : 10.1093/clinids/14.Supplement_1.S68 PMID : 1562698 En línea : https://academic.oup.com/cid/article-abstract/14/Supplement_1/S68/366004 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4367 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000867 AC-1992-006 Archivo digital Producción Científica Artículos científicos Disponible
